Actinic keratoses

Criscione, Vincent D.; Weinstock, Martin A.; Naylor, Mark F.; Luque, C Espildora; Eide, Melody J.; Bingham, Stephen F.

doi:10.1002/cncr.24284

Cited by 367 publications

(145 citation statements)

References 31 publications

Supporting

Mentioning

118

Contrasting

Unclassified

Order By: Relevance

“…Early biopsy of skin lesions developing during sorafenib therapy is encouraged to clarify the nature of the lesion, in particular since BCC can clinically be mistaken as AK [26]. …”

Section: Discussionmentioning

confidence: 99%

Does Basal Cell Carcinoma Belong to the Spectrum of Sorafenib-Induced Epithelial Skin Cancers?

Degen

Satzger²,

Voelker³

et al. 2010

Dermatology

View full text Add to dashboard Cite

The multikinase inhibitor sorafenib is therapeutically used in various malignancies. Multiple cutaneous side effects are well described but recent reports indicated a possible association of epithelial skin cancer growth during sorafenib therapy. To our knowledge, few cases of actinic keratoses and variants of squamous cell carcinomas associated with sorafenib have been published. We report 2 patients who developed a basal cell carcinoma (BCC) while treated with sorafenib. Interestingly BCC is a tumor which has not been described yet in association with sorafenib therapy. The tumors were excised completely. After termination of sorafenib treatment, no new BCCs or other epithelial skin cancers occurred. There is accumulating evidence in the literature that sorafenib and possibly other targeted agents are associated with an increased occurrence of epithelial skin cancers. These observations are summarized here and complemented by the new observation that al- so BCCs might be associated with sorafenib therapy. The pathogenetic mechanisms are unclear so far but induction of the mitogen-activated protein kinase pathway in wild-type RAF cells by RAF inhibitors might play a role. Patients should be informed of this possible side effect and undergo regular dermatological controls before and during sorafenib therapy.

show abstract

“…Early biopsy of skin lesions developing during sorafenib therapy is encouraged to clarify the nature of the lesion, in particular since BCC can clinically be mistaken as AK [26]. …”

Section: Discussionmentioning

confidence: 99%

Does Basal Cell Carcinoma Belong to the Spectrum of Sorafenib-Induced Epithelial Skin Cancers?

Degen

Satzger²,

Voelker³

et al. 2010

Dermatology

View full text Add to dashboard Cite

show abstract

“…Approximately 65% of cSCCs arise from premalignant precursor conditions such as actinic keratosis (9). Organ transplant recipients on immunosuppression regimens are 65-times more likely to develop cSCC (10).…”

Section: Introductionmentioning

confidence: 99%

Genomic Analysis of Metastatic Cutaneous Squamous Cell Carcinoma

Hanna

Laga

et al. 2015

Clinical Cancer Research

252

279

View full text Add to dashboard Cite

Purpose A rare 5% of cutaneous squamous cell carcinomas metastasize, lack FDA-approved therapies, and carry a poor prognosis. Our aim was to identify recurrent genomic alterations in this little-studied population of metastatic cSCCs. Experimental Design We performed targeted sequencing of 504 cancer-associated genes on lymph node metastases in 29 patients with cSCC and identified mutations and somatic copy number alterations associated with metastatic cSCC. We determined significantly mutated, deleted and amplified genes and associated genomic alterations with clinical variables. Results The cSCC genome is heterogeneous with widely varying numbers of genomic alterations and does not appear to be associated with HPV. We found previously identified recurrently altered genes (TP53, CDKN2A, NOTCH1/2) but also a wide spectrum of oncogenic mutations affecting RAS/RTK/PI3K, squamous differentiation, cell cycle, and chromatin remodeling pathway genes. Specific mutations in known oncogenic drivers and pathways were correlated with inferior patient outcomes. Our results suggest potential therapeutic targets in metastatic cSCC including PIK3CA, FGFR3, BRAF, and EGFR, similar to those reported in SCCs of the lung and head and neck, suggesting that clinical trials could be developed to accrue patients with SCCs from multiple sites of origin. Conclusions We have genomically characterized a rare cohort of 29 metastatic cSCCs and identified a diverse array of oncogenic alterations that can guide future studies of this disease.

show abstract

“…Besides its potential (0.6-20%) for turning into invasive neoplasms, they reflect the accumulated photodamage and indicate a larger risk of developing skin cancers in every region affected by the disease. [1][2][3][4][5] They are common in sun-exposed areas of elderly fairskinned people, representing 5.1% of complaints in dermatological consultations in Brazil. In Australia, it is estimated that 40-50% of the population above 40 years of age presents at least one lesion.…”

Section: Introductionmentioning

confidence: 99%